Hamed Javan MD

Jewish General Hospital

Dr Javan is a medical doctor, completed Master of Experimental Medicine-Oncology program at McGill University, and working as clinical/research at the Jewish General Hospital with Dr Petr Kavan and Dr Gerald Batist. Dr Javan has established a phase II clinical trial for pancreatic cancer. He has a high interest toward investigator-initiated studies, and running new study protocols. Currently, he is preparing new studies in phase II, III and IV for Pancreatic and Colorectal Cancer. His particular research interest is: Pre—operative FOLFIRINOX in pancreatic cancer.

dont miss

Systemic Cancer Therapy: Pancreatic and Colorectal Cancer – Pre-operative FOLFIRINOX in pancreatic cancer

Pancreatic Cancer is a disease with poor prognosis. In 2017, its 5-year net survival rate is only 8% with only 2% in metastatic setting and it is third common cause of cancer related death. Only less than 20% of cases are eligible for surgery at diagnosis, so we tried to evaluate the role preoperative FOLFIRINOX in potentially curable pancreatic cancer in retrospective study and clinical trial.